BioPharma Dive1 min read
saveASCO 2026 Highlights Bispecific Antibodies, ADCs and New Advances in RAS-Targeted and Prostate Cancer Therapies
read at BioPharma Dive ↗Positive
The meeting featured a lively comparison of bispecific antibodies and antibody-drug conjugates as leading modalities in oncology.
Researchers presented data suggesting that targeting mutant RAS proteins is becoming feasible, marking a shift in what was once considered undruggable.
New clinical data indicated a potential step change in treatment options for advanced prostate cancer, with several candidates showing promising activity.
source
This writeup was produced by pharmadog from original reporting by BioPharma Dive. The original article may no longer be reachable at its published URL.
Original headline: “ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that